Press Room (Corporate News) https://stage.mediaroom.com/sanofi/ MediaRoom AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session https://stage.mediaroom.com/sanofi/2026-03-28-AAD-new-results-from-Sanofis-amlitelimab-phase-3-studies-in-atopic-dermatitis-presented-in-late-breaking-research-session Sat, 28 Mar 2026 11:00:00 -0400 https://stage.mediaroom.com/sanofi/2026-03-28-AAD-new-results-from-Sanofis-amlitelimab-phase-3-studies-in-atopic-dermatitis-presented-in-late-breaking-research-session Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease https://stage.mediaroom.com/sanofi/2026-03-18-Sanofis-venglustat-earns-Breakthrough-Therapy-designation-in-the-US-for-type-3-Gaucher-disease Wed, 18 Mar 2026 02:00:00 -0400 https://stage.mediaroom.com/sanofi/2026-03-18-Sanofis-venglustat-earns-Breakthrough-Therapy-designation-in-the-US-for-type-3-Gaucher-disease Sanofi Becomes Official Supporter of the Boston World Cup 2026 Host City https://stage.mediaroom.com/sanofi/2026-02-25-Sanofi-Becomes-Official-Supporter-of-the-Boston-World-Cup-2026-Host-City Wed, 25 Feb 2026 09:00:00 -0500 https://stage.mediaroom.com/sanofi/2026-02-25-Sanofi-Becomes-Official-Supporter-of-the-Boston-World-Cup-2026-Host-City Sanofi announces leadership evolution in Specialty Care Business Unit https://stage.mediaroom.com/sanofi/2026-02-17-Sanofi-announces-leadership-evolution-in-Specialty-Care-Business-Unit Tue, 17 Feb 2026 08:30:00 -0500 https://stage.mediaroom.com/sanofi/2026-02-17-Sanofi-announces-leadership-evolution-in-Specialty-Care-Business-Unit Sanofi’s rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia https://stage.mediaroom.com/sanofi/2026-02-09-Sanofis-rilzabrutinib-designated-breakthrough-therapy-in-the-US-and-orphan-drug-in-Japan-for-the-treatment-of-warm-autoimmune-hemolytic-anemia Mon, 09 Feb 2026 01:00:00 -0500 https://stage.mediaroom.com/sanofi/2026-02-09-Sanofis-rilzabrutinib-designated-breakthrough-therapy-in-the-US-and-orphan-drug-in-Japan-for-the-treatment-of-warm-autoimmune-hemolytic-anemia